Osteoarthritis in 2007

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 222-228

  Krasnokutsky, Svetlana ^a,b   Samuels, Jonathan ^a,b   Abramson, Steven B ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CHONDROITIN; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ESTROGEN; GELATINASE B; GLUCOSAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; RISEDRONIC ACID; SALCATONIN; STROMELYSIN; STROMELYSIN 2; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; METALLOPROTEINASE;

BONE REMODELING; BONE TURNOVER; CARTILAGE CELL; CHONDROPATHY; CLINICAL TRIAL; ENZYME ACTIVATION; GENE LINKAGE DISEQUILIBRIUM; HAPLOTYPE; HEREDITY; HUMAN; IMMUNOHISTOCHEMISTRY; JOINT DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SYNOVIUM; ANIMAL; DRUG ANTAGONISM;

ANIMALS; BIOLOGICAL MARKERS; CALCITONIN; CHONDROITIN; DIPHOSPHONATES; DOXYCYCLINE; GLUCOSAMINE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; METALLOENDOPEPTIDASES; NITRIC OXIDE; OSTEOARTHRITIS;

EID: 38449103301     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Blanco FJ, Guitian R, Vazquez-Martul E de Toro FJ, Galdo FJ. Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum. 1998 Feb;41(2):284-9.
2. Martin JA, Brown TD, Heiner AD, Buckwalter JD. Chondrocyte senescence, joint loading and osteoarthritis. Clin Orthop Relat Res. 2004;(427 Suppl):S96-103.
3. Kuhn K, D'Lima DD, Hashimoto S, Lotz M. Cell death in cartilage. Osteoarthritis Cartilage 2004;12:1-16.
4. van't Hof RJ, Hocking L, Wright PK, Ralston SH. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology (Oxford). 2000;39(9):1004-8.
5. Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum. 1998;41(7):1275-86.
6. Ayral X, Dougados M, Listrat V, et al. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol. 1996;3:698-706.
7. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. Jun 2001;44(6):1237-47.
8. Benito MJ, Veale DJ, FitzGerald O, et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. Sept2005;64(9):1263-7.
9. Masuhara K, Nakai T, Yamaguchi K, et al. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum. 2002;46(10):2625-31.
10. Tchetverikov I, Lohmander LS, Verzijl N, et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis. May 2005;64(5):694-8.
11. Barksby HE, Milner JM, Patterson AM, et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum. Oct 2006;54(10):3244-53.
12. van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology. 2001;103(3):255-61.
13. Bettica P, Cline G, Hart DJ, et al. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: Longitudinal results from the Chingford study. Arthritis Rheum. Dec 2002;46(12):3178-84.
14. Bauer DC, Hunter DJ, Abramson SB, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006;14:723-7.
15. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase-1 expression. Arthritis Rheum. 1996;39:1535-44.
16. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res. 2004;22:742-50.
17. Smith AJ, Keen LJ, Billingham MJ, et al. Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis. Genes Immun. 2004;5:451-60.
18. Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005;32:1317-23.
19. Chevalier X, Goupille P, Beaulieu AD, et al. Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra in patients with osteoarthritis of the knee. Arthritis Rheum. 2005;52:(Suppl);S507.
20. Martel-Pelletier J, Mineau F, Jolicoeur FC, et al. In vitro effects of diacerhein and rhein on IL-1 and TNFα systems in human osteoarthritc synovium and chondrocytes. J Rheumatol. 1998;25:753-62.
21. Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44:2539-47.
22. Pham T, Le Henanff A, Ravaud P, et al. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004;63:1611-7.
23. Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br. 1998;80:907-8.
24. van Marle S, van Vliet A, Sollie F, et al. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005;43(6):282-93.
25. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther. 2005;7:R625-33.
26. Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow X-ray progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee OA structural arthritis (KOSTAR) study. Arthritis Rheum. Nov 2006;54:3494-507.
27. Buckland-Wright JC, Messent EA, Bingham CO III, et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology. 2007;46(2):257-264.
28. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis Arthritis Rheum. 2004;50:3516-25.
29. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci. 1996;93:14014-9.
30. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005;52:2015-25.
31. van den Berg WB, van de Loo F, Joosten LA, Arntz OJ. Animal models of arthritis in NOS2-deficient mice. Osteoarthritis Cartilage. 1999;7:413-5.
32. Pelletier J, Jovanovic D, Fernandes JC, et al. Reduction in the structural changes of experimental osteoarthritis by a nitric oxide inhibitor. Osteoarthritis Cartilage. 1999;7:416-8.
33. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56:2267-77.
34. Frech TM, Clegg DO. The utility of nutraceuticals in the treatment of osteoarthritis. Curr Rheumatol Reports. 2007;9:25-30.
35. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2:CD002946.
36. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251-6.
37. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis. Arch Intern Med. 2002;162:2113-23.
38. Mazzuca SA, Brandt KD, Lane KA, et al. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum. 2002;46:1223-7.
39. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808.
40. Karsdal MA, Tanko LB, Riis BJ, et al. Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA? Osteoarthritis Cartilage. 2006;14:617-624.
41. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205-11.